SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-020697
Filing Date
2023-06-02
Accepted
2023-06-02 17:18:31
Documents
12
Period of Report
2023-05-30
Items
Item 4.01: Changes in Registrant's Certifying Accountant

Document Format Files

Seq Description Document Type Size
1 8-K cpix-20230530.htm   iXBRL 8-K 33099
  Complete submission text file 0001628280-23-020697.txt   169870

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20230530.xsd EX-101.SCH 2011
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20230530_lab.xml EX-101.LAB 24152
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20230530_pre.xml EX-101.PRE 12609
6 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20230530_htm.xml XML 11027
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33637 | Film No.: 23990166
SIC: 2834 Pharmaceutical Preparations